Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. Chief Business Officer Mike Kelliher reported selling a total of 7,248 shares of common stock on May 21, 2026 at a price of $6.2675 per share in three separate transactions. A footnote explains these sales were an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover applicable withholding taxes. This indicates the activity was a tax-related mechanism tied to equity compensation rather than a discretionary reduction of his investment in the company.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported multiple open-market sales totaling 6,989 shares of common stock at $6.2675 per share. According to the footnote, these transactions were automatic sell-to-cover trades tied to RSU vesting, executed solely to pay withholding taxes. Williams continued to hold 429,093 shares directly after the transactions.
ARDELYX, INC. President & CEO Michael Raab reported routine sales of company common stock tied to restricted stock unit (RSU) vesting. On May 21, 2026, entities associated with him sold a total of 54,748 shares of Ardelyx common stock at $6.2675 per share.
According to the disclosure, these transactions were an automatic sell-to-cover required by the original RSU grant terms, and the shares were sold solely to cover applicable withholding taxes at vesting. After these sales, Raab directly held about 1,759,848 common shares, with additional indirect holdings of 1,000 shares and 24,364 shares held in family-related trusts.
Ardelyx, Inc. officer Mike Kelliher reported a planned sale of 10,500 shares of common stock, with an aggregate market value of $65,415 and an approximate sale date of May 19, 2026. The notice says the shares are to be sold upon vesting under an automatic sell-to-cover imposed by the initial restricted stock unit grant, solely to cover applicable withholding taxes. The related acquisition table lists 24,986 shares acquired through restricted stock unit vesting on May 19, 2026.
Ardelyx officer Susan Hohenleitner reported a planned sale of 2,650 common shares, with an approximate sale date of May 19, 2026 and aggregate market value of $16,509.50. The shares were acquired through vesting of 5,355 restricted stock units on May 19, 2026. The planned sale is an automatic sell-to-cover under the initial grant, with the shares to be sold upon vesting solely to cover applicable withholding taxes.
ARDELYX, INC. officer Brady James Parker reported a proposed sale of 3,000 common shares, with an aggregate market value of $18,690.00, on approximately May 19, 2026. The notice says the shares are to be sold automatically upon restricted stock unit vesting, solely to cover applicable withholding taxes. It also reports that Parker acquired 6,216 shares through restricted stock unit vesting on May 19, 2026, for services rendered.
Ardelyx, Inc. (ARDX) officer Eric Duane Foster reports a proposed sale of 11,900 common shares, with an aggregate market value of $74,137.00 and an approximate sale date of May 19, 2026. The notice also lists the acquisition of 28,415 common shares through vesting of restricted stock units on May 19, 2026. The stated arrangement is an automatic sell-to-cover imposed by the initial grant terms, with shares sold upon vesting solely to cover applicable withholding taxes.
Ardelyx officer Joseph James Reilly reported plans to sell 4,700 shares of common stock, with an aggregate market value of $29,281, on an approximate date of May 19, 2026. The sale is described as an automatic sell-to-cover upon vesting of restricted stock units, solely to cover applicable withholding taxes.
ARDELYX, INC. officer Michael Raab reported a proposed sale of 44,500 shares of common stock, with an aggregate market value of $277,235 and an approximate sale date of May 19, 2026. The remarks state that the shares are to be sold upon vesting of the restricted stock units under an automatic sell-to-cover imposed by the award terms, solely to cover applicable withholding taxes.
The securities information lists 108,840 shares acquired through vesting of restricted stock units from the issuer for services rendered on May 19, 2026. Recent sales listed include 41,668 shares on April 15, 2026, for gross proceeds of $261,954.22.
Ardelyx, Inc. (ARDX) officer John E. Bishop is named in a notice proposing the sale of 3,700 common shares, with an approximate market value of $23,051.00 and an approximate sale date of May 19, 2026. The notice says the shares are to be sold automatically upon restricted stock unit vesting, solely to cover applicable withholding taxes.